{"id":"bd7e4dec-4455-5553-b1e4-26c17aca2b9e","stable_key":"31b1baa4-4113-5541-b9e7-fe44a5253a07:bv2-nfkb","predicate":"decreases_in_recorded_experiment","statement":"SA reduced p65 and IκB phosphorylation under LPS challenge.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"0aedc454-1f38-5c1d-b715-62bd517071c9","mechanism_event_label":"SA reduced p65 and IκB phosphorylation under LPS challenge.","subject":{"id":"67ad4a8f-1bf6-59e5-90a6-97b7709024d3","slug":"shikimic-acid","display_name":"Shikimic acid","entity_type_key":"small_molecule"},"object":{"id":"f199f874-1b67-56ef-b76a-ebea046d9186","slug":"mouse-bv2-nfkb-phosphorylation","display_name":"Mouse BV2 p65/IκB phosphorylation","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"0aedc454-1f38-5c1d-b715-62bd517071c9","stable_key":"31b1baa4-4113-5541-b9e7-fe44a5253a07:bv2-nfkb-event","event_type":"experimental_observation","label":"SA reduced p65 and IκB phosphorylation under LPS challenge.","description":"**Inflammatory expression and phosphorylation are distinct endpoints.** In the same BV2/LPS model, shikimic acid reduced Il6, Tnf, Nos2 and Ptgs2 transcripts at 12 h; protein/secretion measurements at 24 h also decreased. At 1 h, p65 and IκB phosphorylation decreased and IκB degradation was reduced. These changes do not establish direct inhibition of COX-2 catalysis or direct binding to every signaling protein. [Shikimic acid (SA) inhibits neuro-inflammation and exerts neuroprotective effects in an LPS-induced <i>in vitro</i> and <i>in vivo</i> model.](https://pubmed.ncbi.nlm.nih.gov/38026972/)","status":"provisional","compartment":null,"participants":[{"entity":{"id":"67ad4a8f-1bf6-59e5-90a6-97b7709024d3","slug":"shikimic-acid","display_name":"Shikimic acid","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"SA plus LPS","sequence_order":0,"notes":""},{"entity":{"id":"f199f874-1b67-56ef-b76a-ebea046d9186","slug":"mouse-bv2-nfkb-phosphorylation","display_name":"Mouse BV2 p65/IκB phosphorylation","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""},{"entity":{"id":"a5745257-0ce7-5ec2-83aa-d42c9905c1a3","slug":"mouse-rela","display_name":"Mouse NF-kappa-B p65 / Rela","entity_type_key":"protein"},"role":"p65 protein","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text retrieved; relevant methods/results/figures reviewed. Selective extraction, not raw-data reanalysis or exhaustive supplemental extraction.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_condition","value_text":"stimulus","comparator":"LPS alone","unit":null,"notes":"Condition belongs to the full experimental contrast; do not separate a joint intervention.","entity":{"slug":"lipopolysaccharide","display_name":"Lipopolysaccharide","entity_type_key":"chemical_species"}},{"dimension":"experimental_condition","value_text":"added","comparator":"LPS alone","unit":null,"notes":"Condition belongs to the full experimental contrast; do not separate a joint intervention.","entity":{"slug":"shikimic-acid","display_name":"Shikimic acid","entity_type_key":"small_molecule"}},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"SA plus LPS\", \"comparator\": \"LPS alone\", \"endpoint\": \"SA reduced p65 and IκB phosphorylation under LPS challenge.\", \"effect_direction\": \"decrease\", \"combination\": \"joint\", \"conditions\": [{\"entity_slug\": \"shikimic-acid\", \"state\": \"added\"}, {\"entity_slug\": \"lipopolysaccharide\", \"state\": \"stimulus\"}]}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; source-derived draft.","entity":null},{"dimension":"experimental_model","value_text":"Mouse BV2; 10 µM SA, LPS 1 µg/mL, 1 h.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"SA reduced p65 and IκB phosphorylation under LPS challenge.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Shikimic acid (SA) inhibits neuro-inflammation and exerts neuroprotective effects in an LPS-induced <i>in vitro</i> and <i>in vivo</i> model. | 2023 | DOI 10.3389/fphar.2023.1265571 | PMID 38026972 | https://pubmed.ncbi.nlm.nih.gov/38026972/ | https://doi.org/10.3389/fphar.2023.1265571 | https://pmc.ncbi.nlm.nih.gov/articles/PMC10652795/","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference lines 63-63; exact primary location described in quoted passage where extracted.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"b8c638d9-8ad9-5328-a4d5-fc80464dee40","evidence_kind":"source_excerpt","locator":"Lines 63-63","start_line":63,"end_line":63,"excerpt":"**Inflammatory expression and phosphorylation are distinct endpoints.** In the same BV2/LPS model, shikimic acid reduced Il6, Tnf, Nos2 and Ptgs2 transcripts at 12 h; protein/secretion measurements at 24 h also decreased. At 1 h, p65 and IκB phosphorylation decreased and IκB degradation was reduced. These changes do not establish direct inhibition of COX-2 catalysis or direct binding to every signaling protein. [Shikimic acid (SA) inhibits neuro-inflammation and exerts neuroprotective effects in an LPS-induced <i>in vitro</i> and <i>in vivo</i> model.](https://pubmed.ncbi.nlm.nih.gov/38026972/)","model_system":"Mouse BV2; 10 µM SA, LPS 1 µg/mL, 1 h.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact excerpt of the retained AI-assisted reviewed reference; primary sources are cited in primary_references and access scope is retained. Not a verbatim quotation from a primary paper.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"e6ae59de-0369-5c2f-8262-57d91302671c","stable_key":"import-31b1baa4-4113-5541-b9e7-fe44a5253a07","title":"Shikimic acid: detailed mechanisms of action (reviewed 5 October 2026)","document_type":"imported_text","citation_label":"Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication.","file_path":"","sha256":"95b1f9e9577661312d67f36e156d2e49326b207f296c1c0e801a5b007fd8e283","revision_id":"cd3237f1-131a-557d-84b5-7543259807b0","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}